TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17523342

Group type: EXPERIMENTAL
Intervention: Omeprazole (OPZ) 20 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (OAC)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lansoprazole (LPZ) 30 mg + AMPC 1500 mg/day + CAM 600 mg/day (LAC)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 10 mg/day + AMPC 1500 mg/day + CAM 600 mg/day (RAC)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Homozygous extensive metabolizer (EM)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Heterozygous EM
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CYP2C19 phenotype - Poor metabolizer
Number of subjects: 135
Study: 15693450

Group type: EXPERIMENTAL
Intervention: 1 week of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 2 weeks of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 1 week of triple therapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 2 weeks of triple therapy
Number of subjects: 82
Study: 11444994

Group type: EXPERIMENTAL
Intervention: Monophasic waveform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polyphasic waveform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All tested waveforms
Number of subjects: 30
Study: 9918641

Group type: EXPERIMENTAL
Intervention: 16 mil superelastic Ni‐Ti archwires
Number of subjects: 155

Group type: COMPARATOR
Intervention: 17.5 mil triple‐stranded steel archwires
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ion-implanted Ni-Ti archwires
Number of subjects: 155
Study: 8050850

Group type: EXPERIMENTAL
Intervention: Short commands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short affective vignettes with tag lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short affective vignettes without tag lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long affective vignettes with tag lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long affective vignettes without tag lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vignettes presented
Number of subjects: 0
Study: 1901638

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot, 3.75 mg intramuscularly every 4 weeks for 24 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot
Number of subjects: 128
Study: 354098

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 125
Study: 31817936

Group type: EXPERIMENTAL
Intervention: Zumba Fitness® (ZF)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Zumba Fitness with Bodyweight strength training (ZF + BW)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 98
Study: 28698987

Group type: EXPERIMENTAL
Intervention: Tri-set (TRI) resistance training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Superset (SS) resistance training
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Traditional (TRAD) resistance training
Number of subjects: 14
Study: 25847559

Group type: EXPERIMENTAL
Intervention: 1mg/kg Ginkgo biloba extract (G group n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (D group n=30)
Number of subjects: 60
Study: 22833264

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) view consisting of an endoscopic video fused with anatomic contours
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard endoscopic view (control)
Number of subjects: 32
Study: 20929947

Group type: EXPERIMENTAL
Intervention: TYL intervention (Transforming Your Life)
Number of subjects: 54

Group type: COMPARATOR
Intervention: LEARN intervention (traditional behavioral weight loss program)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: TYL intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: LEARN intervention
Number of subjects: 54
Study: 19438787

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Air and papaverine
Number of subjects: 84
Study: 17062048

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 30
Study: 16166876

Group type: EXPERIMENTAL
Intervention: Perfect health version
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Your-age version
Number of subjects: 1015

Group type: COMPARATOR
Intervention: 20-year-old version
Number of subjects: 1015
Study: 12665408

Group type: EXPERIMENTAL
Intervention: Mobilization with movement for the elbow
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 10416459

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training for 18 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dropout group (control)
Number of subjects: 93
Study: 7559260

Group type: EXPERIMENTAL
Intervention: Zaditen SRO 4 mg once daily
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Zaditen SRO 2 mg once daily
Number of subjects: 362

Group type: COMPARATOR
Intervention: Zaditen Standard Form 1 mg twice daily
Number of subjects: 362
Study: 2196774

Group type: EXPERIMENTAL
Intervention: Intravenous captopril (n = 8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 12
Study: 7025625

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Propranolol 280 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Propranolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12445036

Group type: EXPERIMENTAL
Intervention: NewRinsed spacer
Number of subjects: 25

Group type: COMPARATOR
Intervention: Primed1 spacer
Number of subjects: 25

Group type: COMPARATOR
Intervention: Used spacer
Number of subjects: 25
Study: 31924277

Group type: EXPERIMENTAL
Intervention: Medrave 4 program for data extraction
Number of subjects: 86
Study: 29199100

Group type: EXPERIMENTAL
Intervention: Universal antiretroviral therapy (ART) with fixed-dose combination of tenofovir, emtricitabine, and efavirenz, regardless of CD4 cell count.
Number of subjects: 26518

Group type: COMPARATOR
Intervention: Control group followed national guidelines for ART initiation (initially ≤350 cells per μL and <500 cells per μL from January 2015).
Number of subjects: 26518

Group type: COMPARATOR
Intervention: Both intervention and control groups.
Number of subjects: 26518
Study: 27585969

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 h
Number of subjects: 761

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h) plus aztreonam (1 g every 8 h)
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 h and Vancomycin plus aztreonam
Number of subjects: 761
Study: 24395288

Group type: EXPERIMENTAL
Intervention: Calcium and cholecalciferol supplementation (1,000 mg/day calcium and 800 IU cholecalciferol)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Nutritional counseling with supplementation
Number of subjects: 275
Study: 26856037

Group type: EXPERIMENTAL
Intervention: 15 minute alarm reminder system
Number of subjects: 127

Group type: COMPARATOR
Intervention: Non-alarm control
Number of subjects: 127
Study: 20332588

Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Sitagliptin (all doses)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 18618189

Group type: EXPERIMENTAL
Intervention: Quality Improvement plus brief telephone coaching (QI-plus)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Quality Improvement only (QI-only)
Number of subjects: 719
Study: 16284747

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 2838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study: 12392456

Group type: EXPERIMENTAL
Intervention: Impedance respirometry
Number of subjects: 79
Study: 9915432

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy
Number of subjects: 147

Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 147
Study: 7751881

Group type: EXPERIMENTAL
Intervention: modified LSA2L2
Number of subjects: 281

Group type: COMPARATOR
Intervention: ADCOMP (which included daunorubicin and asparaginase)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 281
Study: 2267964

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Mefloquine (250 mg weekly)
Number of subjects: 253
Study: 7403543

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) before Radionuclide Scanning (RN)
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Radionuclide Scanning (RN) before Computed Tomography (CT)
Number of subjects: 1643
Study: 30892987

Group type: EXPERIMENTAL
Intervention: Encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab
Number of subjects: 30
Study: 28759172

Group type: EXPERIMENTAL
Intervention: Oxytocin-induced labor
Number of subjects: 64

Group type: COMPARATOR
Intervention: No labor induction (Control)
Number of subjects: 64
Study: 26219161

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: General Anesthesia combined with Continuous Epidural Anesthesia (GCEA)
Number of subjects: 64
Study: 23512648

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 21812889

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Atorvastatin 20 or 40 mg
Number of subjects: 279

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 279
Study: 19624299

Group type: COMPARATOR
Intervention: CRT5 (five-field conformal radiotherapy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: IMRT(for) (forward-planned intensity-modulated radiotherapy)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IMRT(inv) (inverse-planned multi-segment solution)
Number of subjects: 18
Study: 16449339

Group type: EXPERIMENTAL
Intervention: sc PTH (1-84), 100 mug/d
Number of subjects: 238
Study: 15328551

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 15
Study: 11035889

Group type: EXPERIMENTAL
Intervention: Pramipexole, 0.5 mg 3 times per day, with levodopa placebo (n = 151)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Carbidopa/levodopa, 25/100 mg 3 times per day, with pramipexole placebo (n = 150)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pramipexole (n = 39)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa (n = 39)
Number of subjects: 301
Study: 8848410

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of neuropeptide Y (NPY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of noradrenaline (NA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of endothelin‐1,2 (ET‐1,2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of alpha atrial natriuretic polypeptide (ANP)
Number of subjects: 0
Study: 2062628

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (ACV) booster at 19 months
Number of subjects: 41
Study: 6825123

Group type: EXPERIMENTAL
Intervention: Tricyclic nucleoside phosphate (iv infusion over 15 minutes once every 3 weeks, doses ranged from 25 to 350 mg/m2)
Number of subjects: 20
Study: 31310929

Group type: EXPERIMENTAL
Intervention: Augmented Depression Therapy (ADepT)
Number of subjects: 11
Study: 27474364

Group type: EXPERIMENTAL
Intervention: Lingualized occlusion (LO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fully bilateral balanced articulation (FBBA)
Number of subjects: 60
Study: 26077241

Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparator (progestin or investigator choice chemotherapy)
Number of subjects: 130
Study: 23585665

Group type: EXPERIMENTAL
Intervention: canagliflozin 100 mg/d for 8 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment intervention
Number of subjects: 28
Study: 22226269

Group type: EXPERIMENTAL
Intervention: NovoTwist insulin pen needle
Number of subjects: 30
Study: 19358940

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3429
Study: 16423633

Group type: EXPERIMENTAL
Intervention: High-protein, low-carbohydrate diet (20:30:50 carbohydrate-protein-fat ratio)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (55:15:30 carbohydrate-protein-fat ratio)
Number of subjects: 0
Study: 15265190

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 33
Study: 11412156

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg.4 h‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g.6 h‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine alone (Control)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Morphine alone)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nefopam group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propacetamol group
Number of subjects: 120
Study: 9524832

Group type: EXPERIMENTAL
Intervention: Azithromycin (1,200 mg once weekly)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 8014323

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2512804

Group type: EXPERIMENTAL
Intervention: Crystalline zinc insulin (CZI) in each liter of TPN solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional insulin (control group)
Number of subjects: 0
Study: 5031712

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study: 30479538

Group type: COMPARATOR
Intervention: 1 minute stair climbing
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 minutes stair climbing
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10 minutes stair climbing
Number of subjects: 30
Study: 31590681

Group type: EXPERIMENTAL
Intervention: Internet Cognitive Therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 40
Study: 27897186

Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT) - Swedish massage to upper body
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guided Imagery (GI) relaxation
Number of subjects: 40
Study: 25500799

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 548

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study: 23884387

Group type: EXPERIMENTAL
Intervention: Beetroot bread (BB) - 200 g containing 100 g beetroot (1.1 mmol nitrate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control white bread (CB) - 200 g (0 g beetroot, 0.01 mmol nitrate)
Number of subjects: 23
Study: 21642845

Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary rehabilitation program plus oral medication
Number of subjects: 197

Group type: COMPARATOR
Intervention: Oral medication alone
Number of subjects: 197
Study: 18423869

Group type: EXPERIMENTAL
Intervention: Antioxidants plus zinc supplementation
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 876

Group type: COMPARATOR
Intervention: Antioxidants supplementation
Number of subjects: 876

Group type: COMPARATOR
Intervention: No zinc supplementation
Number of subjects: 876

Group type: COMPARATOR
Intervention: No antioxidants supplementation
Number of subjects: 876
Study: 16490803

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg administered with a high-fat/high-calorie meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telbivudine 600 mg administered without a high-fat/high-calorie meal (fasting)
Number of subjects: 0
Study: 12427406

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 454
Study: 10353617

Group type: EXPERIMENTAL
Intervention: Amifostine pretreatment (910 mg/m2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin, adriamycin, cyclophosphamide)
Number of subjects: 19
Study: 8668059

Group type: EXPERIMENTAL
Intervention: 100 mg esmolol IV
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 200 mg esmolol IV
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1971318

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin and metronidazole with CBS)
Number of subjects: 50
Study: 7395772

Group type: EXPERIMENTAL
Intervention: Carnitine (0.5 g for 8 weeks, then 1.0 g for 6 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6387632

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both nutritional supplementation and relaxation training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neither nutritional supplementation nor relaxation training (Control)
Number of subjects: 55
Study: 30939091

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) in low TILs group
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) in high TILs group
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: High TILs
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Grade 3 vs Grade 1
Number of subjects: 1178
Study: 29580569

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 58
Study: 28361826

Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg once daily for six months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no carvedilol)
Number of subjects: 54
Study: 25300260

Group type: EXPERIMENTAL
Intervention: Lifestyle advice (n = 1,108)
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Standard care (n = 1,104)
Number of subjects: 2212
Study: 22244567

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (4 periods of 5 minutes of lower limb ischemia intercalated with 5 minutes of reperfusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study: 21203731

Group type: EXPERIMENTAL
Intervention: Citric acid 25 percent by brushing for 1 or 3 minutes
Number of subjects: 270

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 270
Study: 17933193

Group type: EXPERIMENTAL
Intervention: 8-week periodized resistance training (experimental group, n = 10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 10)
Number of subjects: 16
Study: 16097906

Group type: EXPERIMENTAL
Intervention: Self-guided Internet coping group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 62
Study: 11807353

Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels
Number of subjects: 99

Group type: COMPARATOR
Intervention: No division of short gastric vessels
Number of subjects: 99
Study: 9873217

Group type: EXPERIMENTAL
Intervention: Hard water (Ca2+ 255 mg/l)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Soft water (Ca2+ 22 mg/l, Fiuggi water)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 18
Study: 7668962

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hands-assisted standing-up
Number of subjects: 2
Study: 2140325

Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7031872

Group type: EXPERIMENTAL
Intervention: 3 daily doses of 220 mg oral zinc sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30345895

Group type: EXPERIMENTAL
Intervention: Identification of agricultural stressors
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Perceived effects of agricultural stressors
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Coping mechanisms for agricultural stressors
Number of subjects: 70
Study: 29895590

Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation using therapeutic levels of ultrasound energy (n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham application of diagnostic ultrasound (n=11)
Number of subjects: 23
Study: 26801470

Group type: EXPERIMENTAL
Intervention: Self‐management of Osteoarthritis and Low back pain through Activity and Skills (SOLAS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual individual physiotherapy
Number of subjects: 0